Hycor Biomedical

Executive Summary

Hycor Biomedical is a private diagnostics company based in Uden, Netherlands, specializing in immunoassay analyzers and allergy testing solutions. Founded in 1985, the company offers the NOVEOS Immunoassay Analyzer and the HYTEC 288 Plus, targeting mid- to high-volume laboratories that process routine allergy tests. Their products are designed to address common challenges in lab workflows, such as throughput, automation, and accuracy. With a focus on the allergy diagnostics niche, Hycor competes against larger players like Siemens and Thermo Fisher but differentiates through specialized, high-performance analyzers. The company operates primarily in Europe and is exploring expansion into other regions. Despite being privately held with limited financial disclosure, Hycor's established product portfolio and long operational history suggest steady revenue from installed base and consumable sales. Growth drivers include increasing allergy prevalence and the trend toward automated diagnostics. The company's private status implies independence from short-term earnings pressure, enabling long-term R&D investments. However, reliance on a narrow product line and limited geographical reach present risks. Hycor's next phase will likely hinge on regulatory clearances and partnerships to scale distribution.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) clearance for NOVEOS Analyzer40% success
• Q2 2026Partnership with major European lab network for allergy testing50% success
• Q3 2026Launch of expanded allergy test panel for HYTEC 288 Plus60% success